State Street Corp Cyclerion Therapeutics, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $63 - $174	-135 Reduced 0.12%	115,414 $63,000
Q1 2022 May 16, 2022	BUY	$0.96 - $1.78 $4,538 - $8,415	4,728 Added 4.27%	115,549 $128,000
Q4 2021 Feb 14, 2022	BUY	$1.56 - $2.99 $32,916 - $63,089	21,100 Added 23.52%	110,821 $191,000
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $17,472 - $26,432	6,400 Added 7.68%	89,721 $275,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.29 $690,678 - $1.36 Million	-316,825 Reduced 79.18%	83,321 $325,000
Q1 2021 May 17, 2021	SELL	$2.69 - $5.12 $73,046 - $139,033	-27,155 Reduced 6.36%	400,146 $1.12 Million
Q4 2020 Feb 16, 2021	SELL	$2.25 - $7.12 $26,484 - $83,809	-11,771 Reduced 2.68%	427,301 $1.31 Million
Q3 2020 Nov 10, 2020	SELL	$3.46 - $8.39 $211,087 - $511,857	-61,008 Reduced 12.2%	439,072 $2.67 Million
Q2 2020 Aug 14, 2020	SELL	$2.37 - $7.14 $88,249 - $265,865	-37,236 Reduced 6.93%	500,080 $2.96 Million
Q1 2020 May 11, 2020	BUY	$2.46 - $5.84 $1.32 Million - $3.14 Million	537,316 New	537,316 $1.42 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $145M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.